BROMAZEPAM DIN 02171872
Health Canada record
| Active ingredient(s) | BROMAZEPAM 6 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | TARGETED SUBSTANCES (CDSA IV) |
| Class | Human |
| ATC | N05BA08 BROMAZEPAM |
| Original market date | 31-Dec-1995 |
| Current status date | 19-Jul-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Apotex Inc — licence 100375, currently licensed, last inspection rating C (2026-04-21).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing BROMAZEPAM
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02177188 | APO-BROMAZEPAM | APOTEX INC | Tablet | BROMAZEPAM 6 MG | Marketed |
| 02177161 | APO-BROMAZEPAM | APOTEX INC | Tablet | BROMAZEPAM 3 MG | Marketed |
| 02171856 | BROMAZEPAM | APOTEX INC | Tablet | BROMAZEPAM 1.5 MG | Approved |
| 02171864 | BROMAZEPAM | APOTEX INC | Tablet | BROMAZEPAM 3 MG | Approved |
| 02230584 | TEVA-BROMAZEPAM | TEVA CANADA LIMITED | Tablet | BROMAZEPAM 3 MG | Marketed |
| 02230585 | TEVA-BROMAZEPAM | TEVA CANADA LIMITED | Tablet | BROMAZEPAM 6 MG | Marketed |
| 02167808 | ALTI-BROMAZEPAM 1.5MG TABLETS | ALTIMED PHARMA INC. | Tablet | BROMAZEPAM 1.5 MG | Cancelled Post Market |
| 02167816 | ALTI-BROMAZEPAM 3MG TABLETS | ALTIMED PHARMA INC. | Tablet | BROMAZEPAM 3 MG | Cancelled Post Market |
| 02167824 | ALTI-BROMAZEPAM 6MG TABLETS | ALTIMED PHARMA INC. | Tablet | BROMAZEPAM 6 MG | Cancelled Post Market |
| 02177153 | APO-BROMAZEPAM | APOTEX INC | Tablet | BROMAZEPAM 1.5 MG | Dormant |
| 02220512 | BROMAZEPAM-1.5 - TAB 1.5MG | PRO DOC LIMITEE | Tablet | BROMAZEPAM 1.5 MG | Cancelled Post Market |
| 02220520 | BROMAZEPAM-3 - TAB 3MG | PRO DOC LIMITEE | Tablet | BROMAZEPAM 3 MG | Cancelled Post Market |
| 02220539 | BROMAZEPAM-6 - TAB 6MG | PRO DOC LIMITEE | Tablet | BROMAZEPAM 6 MG | Cancelled Post Market |
| 02192713 | GEN-BROMAZEPAM - TAB 3MG | GENPHARM ULC | Tablet | BROMAZEPAM 3 MG | Cancelled Post Market |
| 02192721 | GEN-BROMAZEPAM - TAB 6MG | GENPHARM ULC | Tablet | BROMAZEPAM 6 MG | Cancelled Post Market |
| 00682314 | LECTOPAM TAB 1.5MG | HOFFMANN-LA ROCHE LIMITED | Tablet | BROMAZEPAM 1.5 MG | Cancelled Post Market |
| 00518123 | LECTOPAM TAB 3MG | HOFFMANN-LA ROCHE LIMITED | Tablet | BROMAZEPAM 3 MG | Cancelled Post Market |
| 00518131 | LECTOPAM TAB 6MG | HOFFMANN-LA ROCHE LIMITED | Tablet | BROMAZEPAM 6 MG | Cancelled Post Market |
| 02192705 | MYLAN-BROMAZEPAM | MYLAN PHARMACEUTICALS ULC | Tablet | BROMAZEPAM 1.5 MG | Cancelled Post Market |
| 02232556 | PENTA-BROMAZEPAM TABLETS | PENTAPHARM LTD. | Tablet | BROMAZEPAM 3 MG | Cancelled Post Market |
| 02232558 | PENTA-BROMAZEPAM TABLETS | PENTAPHARM LTD. | Tablet | BROMAZEPAM 6 MG | Cancelled (Unreturned Annual) |
| 02242152 | RIVA-BROMAZEPAM 3 MG | LABORATOIRE RIVA INC. | Tablet | BROMAZEPAM 3 MG | Cancelled Pre Market |
| 02242153 | RIVA-BROMAZEPAM 6 MG | LABORATOIRE RIVA INC. | Tablet | BROMAZEPAM 6 MG | Cancelled Pre Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26284 | 2021-07-19 | New Drug Submission (NDS) | |
| 4885 | 1995-06-26 | New Drug Submission (NDS) |
International API supply for BROMAZEPAM
4 valid EDQM Certificates of Suitability from 4 holders.
Request a quote for BROMAZEPAM